New Perceptions in the Cardioprotective Effect of Metformin Against Isoproterenol Induced Cardiotoxicity in Male Rats

Yazarlar

  • Yahya ghanim Al-Qaisy University of Uruk College of Pharmacy
  • Inam Sameh Arif Mustansyria University, College of Medicine
  • Muthanna Ibraheem Al-ezzi University of Uruk College of Pharmacy

Background and objective: Recent clinical trials have shown that metformin improves clinical cardiovascular outcome in type-2 diabetic patients independently of its insulin-sensitizing effect. This study was sought to evaluate the potential cardioprotective effects of metformin on isoproterenol-induced cardiac stress in diabetic and non-diabetic rats. Materials and Methods: Diabetes was induced by using streptozocin (60 mg/kg, i.p.) while non-diabetic rats received saline. Rats in both experimental groups were then randomized to receive different doses of metformin (75, 150, 300 mg/kg i.p.) for 6 weeks. Cardiac stress was induced by isoproterenol (150 mg/kg i.p.) for two successive days. Specific biomarkers of tissue injury, namely brain natriuretic peptide (BNP), cardiac troponin-T (cTn-T), matrix metalloproteinase (MMP), tissue necrotic factor-α (TNF), were assessed. Data were analysed using one-way ANOVA followed by Newman Keuls post hoc test Results: The results showed that metformin significantly limited isoproterenol-induced myocardial injury in both diabetic and non-diabetic rats. Metformin significantly decreased the elevated serum levels of brain natriuretic peptide (BNP), matrix metalloproteinase (MMP), cardiac troponin t (cTn-T) which was induced by isoproterenol. It also limited expression of tissue necrotic factor-α (TNF-α) following the cardiac injury in diabetic and non-diabetic rats.

Anahtar Kelimeler:

Metformin- Type 2 diabetes mellitus- cardio-protection- Isoproterenol-induced cardiac stress- Brain natriuretic peptide- Matrix metalloproteinase- cardiac troponin type T- Tumour necrotic factor-α

[1] Abbasi, F., Chu, J.W., McLaughlin, T., Lamendola, C., Leary, E.T., Reaven, G.M., 2004. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 53, 159–164. http://dx.doi.org/10.1016/j.metabol.2003.07.020. PMID: 14767866.

[2] Anker, M.S., von Haehling, S., Anker, S.D., 2009. Biomarkers for Chronic Heart Failure. Herz 34,8, 589–593. DOI: 10.1007/s00059-009-3316-4. PMID: 20024637.

[3] Apaijai, N., Chinda, K., Palee, S., Chattipakorn, S., Chattipakorn, N., 2014. Combined Vildagliptin and Metformin Exert Better Cardioprotection than Monotherapy against Ischemia-Reperfusion Injury in Obese-Insulin Resistant Rats. PLoS ONE 9(7): e102374. https://doi.org/10.1371/journal.pone.0102374. PMID: 25036861.

[4] Bell, R. M., Bøtker, H. E., Carr, R. D., Davidson, S. M., Downey, J. M., Dutka, D. P., … Yellon, D. M. (2016, July 1). 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Research in Cardiology. Dr. Dietrich Steinkopff Verlag GmbH and Co. KG. https://doi.org/10.1007/s00395-016-0558-1

[5] Bulluck, H., Yellon, D. M., & Hausenloy, D. J. (2016, March 1). Reducing myocardial infarct size: Challenges and future opportunities. Heart. BMJ Publishing Group. https://doi.org/10.1136/heartjnl-2015-307855

[6] Calvert, J. W., Gundewar, S., Jha, S., Greer, J. J. M., Bestermann, W. H., Tian, R., & Lefer, D. J. (2008). Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS- mediated signaling. Diabetes, 57(3), 696–705. https://doi.org/10.2337/db07-1098

[7] Fryer, R. M., Wang, Y., Hsu, A. K., & Gross, G. J. (2001). Essential activation of PKC-δ in opioid-initiated cardioprotection. American Journal of Physiology - Heart and Circulatory Physiology, 280(3 49-3). https://doi.org/10.1152/ajpheart.2001.280.3.h1346

[8] Cha, H. N., Choi, J. H., Kim, Y. W., Kim, J. Y., Ahn, M. W., & Park, S. Y. (2010). Metformin inhibits isoproterenol-induced cardiac hypertrophy in mice. Korean Journal of Physiology and Pharmacology, 14(6), 377–384. https://doi.org/10.4196/kjpp.2010.14.6.377

[9] Dal, K., Ata, N., Yavuz, B., Sen, O., Deveci, O. S., Aksoz, Z., … Ertugrul, D. T. (2014). The relationship between glycemic control and BNP levels in diabetic patients. Cardiology Journal, 21(3), 252–256. https://doi.org/10.5603/cj.a2013.0109

[10] Davis, B. J., Xie, Z., Viollet, B., & Zou, M. H. (2006). Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes, 55(2), 496–505. https://doi.org/10.2337/diabetes.55.02.06.db05-1064

[11] Derbali, A., Mnafgui, K., Affes, M., Derbali, F., Hajji, R., Gharsallah, N., … El Feki, A. (2015). Cardioprotective effect of linseed oil against isoproterenol-induced myocardial infarction in Wistar rats: a biochemical and electrocardiographic study. Journal of Physiology and Biochemistry, 71(2), 281–288. https://doi.org/10.1007/s13105-015-0411-2

[12] Goldberg, R., Temprosa, M., Otvos, J., Brunzell, J., Marcovina, S., Mather, K., … Barrett-Connor, E. (2013). Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program. Journal of Clinical Endocrinology and Metabolism, 98(10), 3989–3998. https://doi.org/10.1210/jc.2013-1452

[13] Hu, M., Ye, P., Liao, H., Chen, M., & Yang, F. (2016). Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK. Journal of Diabetes Research, 2016. https://doi.org/10.1155/2016/2961954

[14] Huang, N. L., Chiang, S. H., Hsueh, C. H., Liang, Y. J., Chen, Y. J., & Lai, L. P. (2009). Metformin inhibits TNF-α-induced IκB kinase phosphorylation, IκB-α degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. International Journal of Cardiology, 134(2), 169–175. https://doi.org/10.1016/j.ijcard.2008.04.010

[15] Jadeja, R. N., Thounaojam, M. C., Patel, D. K., Devkar, R. V., & Ramachandran, A. V. (2010). Pomegranate (Punica granatum L.) juice supplementation attenuates isoproterenol-induced cardiac necrosis in rats. Cardiovascular Toxicology, 10(3), 174–180. https://doi.org/10.1007/s12012-010-9076-9

[16] Jadhav, S., Ferrell, W., Greer, I. A., Petrie, J. R., Cobbe, S. M., & Sattar, N. (2006). Effects of Metformin on Microvascular Function and Exercise Tolerance in Women With Angina and Normal Coronary Arteries. A Randomized, Double-Blind, Placebo-Controlled Study. Journal of the American College of Cardiology, 48(5), 956–963. https://doi.org/10.1016/j.jacc.2006.04.088

[17] Kewalramani, G., Puthanveetil, P., Wang, F., Kim, M. S., Deppe, S., Abrahani, A., … Rodrigues, B. (2009). AMP-activated protein kinase confers protection against TNF-α-induced cardiac cell death. Cardiovascular Research, 84(1), 42–53. https://doi.org/10.1093/cvr/cvp166

[18] Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002, July 2). Metformin: An update. Annals of Internal Medicine. American College of Physicians. https://doi.org/10.7326/0003-4819-137-1-200207020-00009

[19] Lalu, M. M., Pasini, E., Schulze, C. J., Ferrari-Vivaldi, M., Ferrari-Vivaldi, G., Bachetti, T., & Schulz, R. (2005). Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. European Heart Journal, 26(1), 27–35. https://doi.org/10.1093/eurheartj/ehi007

[20] Lexis, C. P. H., Van Der Horst, I. C. C., & Lipsic, E. (2012, November). Effects of metformin on insulin resistance in heart failure. Which came first: The chicken or the egg? European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfs155

[21] Lexis, C. P. H., Wieringa, W. G., Hiemstra, B., Van Deursen, V. M., Lipsic, E., Van Der Harst, P., … Van Der Horst, I. C. C. (2014). Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovascular Drugs and Therapy, 28(2), 163–171. https://doi.org/10.1007/s10557-013-6504-7

[22] Li, L., Mamputu, J. C., Wiernsperger, N., & Renier, G. (2005). Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: Inhibitory effect of metformin. Diabetes, 54(7), 2227–2234. https://doi.org/10.2337/diabetes.54.7.2227

[23] Lu, J., Ji, J., Meng, H., Wang, D., Jiang, B., Liu, L., … Meng, Q. H. (2013). The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. Cardiovascular Diabetology, 12(1). https://doi.org/10.1186/1475-2840-12-58

[24] Mamputu, J. C., Wiernsperger, N. F., & Renier, G. (2003). Antiatherogenic properties of metformin: The experimental evidence. Diabetes and Metabolism. Elsevier Masson SAS. https://doi.org/10.1016/s1262-3636(03)72790-6

[25] Miura, S., Ohno, I., Suzuki, J., Suzuki, K., Okada, S., Okuyama, A., … Shirato, K. (2003). Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by β-adrenergic stimulation in rats. Journal of Cardiovascular Pharmacology, 42(2), 174–181. https://doi.org/10.1097/00005344-200308000-00004

[26] Morrow, V. A., Foufelle, F., Connell, J. M. C., Petrie, J. R., Gould, G. W., & Salt, I. P. (2003). Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. Journal of Biological Chemistry, 278(34), 31629–31639. https://doi.org/10.1074/jbc.M212831200

[27] Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., … Goodyear, L. J. (2002). Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 51(7), 2074–2081. https://doi.org/10.2337/diabetes.51.7.2074

[28] Peng, W., Zhang, Y., Zhu, W., Cao, C. M., & Xiao, R. P. (2009, October). AMPK and TNF-α at the crossroad of cell survival and death in ischaemic heart. Cardiovascular Research. https://doi.org/10.1093/cvr/cvp272

[29] Sachidanandam, K., Hutchinson, J. R., Elgebaly, M. M., Mezzetti, E. M., Dorrance, A. M., Motamed, K., & Ergul, A. (2009). Glycemic control prevents microvascular remodeling and increased tone in Type 2 diabetes: Link to endothelin-1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 296(4). https://doi.org/10.1152/ajpregu.90537.2008

[30] Timmers, L., Pasterkamp, G., De Hoog, V. C., Arslan, F., Appelman, Y., & De Kleijn, D. P. V. (2012, May 1). The innate immune response in reperfused myocardium. Cardiovascular Research. https://doi.org/10.1093/cvr/cvs018

[31] Soraya, H., Clanachan, A. S., Rameshrad, M., Maleki-Dizaji, N., Ghazi-Khansari, M., & Garjani, A. (2014). Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. European Journal of Pharmacology, 737, 77–84. https://doi.org/10.1016/j.ejphar.2014.05.003

[32] Soraya, H., Farajnia, S., Khani, S., Rameshrad, M., Khorrami, A., Banani, A., … Garjani, A. (2012). Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: Are AMPK and TLRs connected? International Immunopharmacology, 14(4), 785–791. https://doi.org/10.1016/j.intimp.2012.10.01

[33] Vassiliadis, E., Barascuk, N., Didangelos, A., & Karsdal, M. A. (2012). Novel cardiac-specific biomarkers and the cardiovascular continuum. Biomarker Insights. Libertas Academica Ltd. https://doi.org/10.4137/BMI.S9536

[34] Wang, X. F., Zhang, J. Y., Li, L., Zhao, X. Y., Tao, H. L., & Zhang, L. (2011). Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clinical and Experimental Pharmacology and Physiology, 38(2), 94–101. https://doi.org/10.1111/j.1440-1681.2010.05470.x

[35] Yin, M., van der Horst, I. C. C., van Melle, J. P., Qian, C., van Gilst, W. H., Silljé, H. H. W., & de Boer, R. A. (2011). Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 301(2). https://doi.org/10.1152/ajpheart.00054.2011

[36] Zhang, T., Hu, X., Cai, Y., Yi, B., & Wen, Z. (2014). Metformin protects against hyperglycemia-induced cardiomyocytes injury by inhibiting the expressions of receptor for advanced glycation end products and high mobility group box 1 protein. Molecular Biology Reports, 41(3), 1335–1340. https://doi.org/10.1007/s11033-013-2979-3

[37] Zhuo, X. Z., Wu, Y., Ni, Y. J., Liu, J. H., Gong, M., Wang, X. H., … Song, P. (2013). Isoproterenol instigates cardiomyocyte apoptosis and heart failure via AMPK inactivation-mediated endoplasmic reticulum stress. Apoptosis, 18(7), 800–810. https://doi.org/10.1007/s10495-013-0843-5

New Perceptions in the Cardioprotective Effect of Metformin Against Isoproterenol Induced Cardiotoxicity in Male Rats. (2021). Journal Port Science Research, 4(1), 27-34. https://doi.org/10.36371/port.2021.6

Lisans

Telif Hakkı (c) 2021 Journal Port Science Research

Creative Commons License

Bu çalışma Creative Commons Attribution-ShareAlike 4.0 International License ile lisanslanmıştır.

Nasıl Atıf Yapılır

New Perceptions in the Cardioprotective Effect of Metformin Against Isoproterenol Induced Cardiotoxicity in Male Rats. (2021). Journal Port Science Research, 4(1), 27-34. https://doi.org/10.36371/port.2021.6